Rominder SINGH

Dr. Rominder SINGH

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
RSRominder SINGH
Rominder SINGH
MPMark Paxton
Mark Paxton
JAJared Auclair
Jared Auclair
Recent advances in artificial intelligence (AI) tools and techniques can revolutionize the discovery, development, manufacturing, and delivery of new medicines by reducing the time and cost involved. The biopharmaceutical industry is a highly regulated sector where robust regulatory oversight is essential to ensure human therapeutics’ quality, efficacy, and safety. This Perspective examines the challenges of regulating AI-driven technologies in drug discovery and development. As AI is anticipated to play an unprecedented role in transforming drug development, the critical question is not whether to regulate these advancements but how to do so effectively. Here, we evaluate current global drug regulatory practices, discuss gaps and unknowns, and provide recommendations on addressing these issues to facilitate effective regulations of AI-driven innovation in the biopharmaceutical industry.

12 May 2024 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
PDF file
RSRominder SINGH
Rominder SINGH
WWWilliam Wang
William Wang
ACAloka Chakravarty
Aloka Chakravarty
JWJun Wang
Jun Wang
YUYoshiaki Uyama
Yoshiaki Uyama

13 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Jared Robert AuclairJared Robert Auclair
Jared Robert Auclair
JJJeewon Joung
Jeewon Joung
MSMaya Abigail Singh
Maya Abigail Singh
GDGael Debauve Debauve
Gael Debauve Debauve
RSRominder SINGH
Rominder SINGH
Cell and Gene Therapy (CGT) represents a paradigm shift in medicine, offering curative potential for previously intractable diseases. However, the complexity, high cost, and manufacturing challenges inherent in developing, producing, and administering these therapies hinder their widespread accessibility. This review examines the critical and increasingly synergistic role of Artificial Intelligence (AI) and Machine Learning (ML) in overcoming these barriers across the entire CGT lifecycle, from discovery and construct design to smart manufacturing, clinical translation, and regulatory applications. We analyze how AI-driven approaches fundamentally differ from conventional methods, facilitating rapid construct optimization, generating highly predictive translational models, enabling the vision of autonomous, digital-twin-driven manufacturing, and establishing new paradigms for pharmacovigilance and regulatory oversight. The integration of AI is not merely an incremental improvement but a foundational transformation, positioning CGT to move from niche, bespoke treatments to scalable, accessible, and highly personalized medical modalities. We conclude by discussing current gaps, particularly data scarcity and regulatory uncertainty, and outlining a roadmap to realize the full potential of AI-enabled CGT.

1 October 2024 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
JRJay G. Ronquillo
Jay G. Ronquillo
BSBrett South
Brett South
PNPrakash Naik
Prakash Naik
RSRominder SINGH
Rominder SINGH
MJMagdia De Jesus
Magdia De Jesus
AHAida Habtezion
Aida Habtezion
PURPOSE: Cancer drug development remains a critical but challenging process that affects millions of patients and their families. Using biomedical informatics and artificial intelligence (AI) approaches, we assessed the regulatory and translational research landscape defining successful first-in-class drugs for patients with cancer. METHODS: This is a retrospective observational study of all novel first-in-class drugs approved by the US Food and Drug Administration (FDA) from 2018 to 2022, stratified by cancer versus noncancer drugs. A biomedical informatics pipeline leveraging interoperability standards and ChatGPT performed integration and analysis of public databases provided by the FDA, National Institutes of Health, and WHO. RESULTS: Between 2018 and 2022, the FDA approved a total of 247 novel drugs, of which 107 (43.3%) were first-in-class drugs involving a new biologic target. Of these first-in-class drugs, 30 (28%) treatments were indicated for patients with cancer, including 19 (63.3%) for solid tumors and the remaining 11 (36.7%) for hematologic cancers. A median of 68 publications of basic, clinical, and other relevant translational science preceded successful FDA approval of first-in-class cancer drugs, with oncology-related treatments involving fewer median years of target-based research than therapies not related to cancer (33 v 43 years; P < .05). Overall, 94.4% of first-in-class drugs had at least 25 years of target-related research papers, while 85.5% of first-in-class drugs had at least 10 years of translational research publications. CONCLUSION: Novel first-in-class cancer treatments are defined by diverse clinical indications, personalized molecular targets, dependence on expedited regulatory pathways, and translational research metrics reflecting this complex landscape. Biomedical informatics and AI provide scalable, data-driven ways to assess and even address important challenges in the drug development pipeline.

9 March 2026 in Frontiers in Drug Safety and Regulation
Verified
Journal Article
Open access
PDF file
RSRominder SINGH
Rominder SINGH
MPMukesh Pareek
Mukesh Pareek
MPMichael Prokle
Michael Prokle
ESEduardo Sanchez
Eduardo Sanchez
UHUwe Hohgrawe
Uwe Hohgrawe
JAJared R. Auclair
Jared R. Auclair
Global regulation of artificial intelligence (AI) in healthcare remains highly fragmented. Over 1,000 national AI-related regulations and policy frameworks have been introduced across more than 70 countries, most originating from high-income nations. While major drug regulatory authorities, including those in the United States and European Union, and others like WHO, have issued guidance on AI-enabled systems, platforms, and products, no unified source exists that compiles or compares how these bodies govern the broader AI-enabled therapeutic ecosystem. This lack of alignment contributes to disparities in interpretation and implementation, potentially delaying global access to novel AI-based therapies. To address this gap, we developed AI-enabled, continuously updated regulatory intelligence system (AICURIS), a comprehensive AI-enabled regulatory intelligence system trained initially on AI-related regulations from sentinel regulatory authorities (e.g., FDA, EMA, WHO), designed to continuously monitor and classify AI-relevant regulatory content and to enable structured comparison, identification of alignment and divergence, and evidence-informed discussion on regulatory convergence as its coverage expands across jurisdictions. Using over 400,000 regulatory documents published since 2019, an AI-enabled hybrid semantic similarity and keyword scoring model achieved 95% recall for high-confidence AI-related content. The following results summarize the key findings from the analysis of AI-related regulatory documents across three major agencies (United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO)). The findings are presented in six parts: (1) document corpus composition and filtering outcomes, (2) model optimization, (3) classification model performance, (4) classification ensemble model validation, (5) cross-agency bias mitigation, and (6) real-time monitoring capabilities. This study demonstrates that AI-powered, data-driven approaches can effectively federate AI-related drug regulations across jurisdictions, reducing global disparities, and enabling more equitable, collaborative, and efficient human therapeutics innovation.